IP Library Granted Patent US 8,852,594
Granted Patent B2
US 8,852,594 · App. 13/486,569 · Granted Oct 7, 2014

Compositions and methods for the therapy and diagnosis of cytomegalovirus infections

Inventor: Ole Olsen (Everett, WA)
Assignee: Theraclone Sciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,852,594
App. No.
13/486,569
Granted
Oct 7, 2014
Kind
B2
Abstract

The present invention provides anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.

Claims (12)

1. A method for the treatment of a CMV infection in a subject, comprising administering to the subject a composition comprising an isolated anti-CMV antibody, or antigen-binding fragment thereof, wherein said antibody comprises:

(a) a V H region comprising

(i) a V H CDR1 region comprising the amino acid sequence of SSNGIH (SEQ ID NO: 57);

(ii) a V H CDR2 region comprising the amino acid sequence of VISSDANDKQYADSVKG (SEQ ID NO: 58); and

(iii) a V H CDR3 region comprising the amino acid sequence of DGTCSGGNCYSGLIDY (SEQ ID NO: 59); and

(b) a V L region comprising

(i) a V L CDR1 region comprising the amino acid sequence of RASQSVGGYLA (SEQ ID NO: 43);

(ii) a V L CDR2 region comprising the amino acid sequence of ASIRAT (SEQ ID NO: 64); and

(iii) a V L CDR3 region comprising the amino acid sequence of HQRSNWPPLT (SEQ ID NO: 65).

2. The method of claim 1 , wherein the method further comprises administering an anti-viral treatment.

3. The method of claim 2 , wherein said anti-viral treatment is ganciclovir, foscarnet, cidofovir, valganciclovir, or intravenous immunoglobulin (IVIG).

4. The method of claim 1 , wherein said antibody is administered at a dose sufficient to neutralize CMV infection.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 29, 2015
From: MIDCAP FINANCIAL TRUST, AS AGENT FOR LENDERS
To: THERACLONE SCIENCES, INC.
Reel/Frame 037396/0957 →
SECURITY INTEREST Recorded Nov 19, 2015
From: THERACLONE SCIENCES, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 037146/0817 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2014
From: OLSEN, OLE
To: THERACLONE SCIENCES, INC.
Reel/Frame 033231/0154 →
Continuity (4)
Continuation 13109632 · May 17, 2011
Continuation 12401585 · Mar 10, 2009
Provisional Application 61068798 · Mar 10, 2008
Related Publication 20120263734A1 · Oct 18, 2012